Key result
Adding 10 mg/day rosuvastatin to valsartan significantly improved flow-mediated dilation compared to valsartan alone in nondiabetic peritoneal dialysis patients (P=0.02 for between-group difference).
Why the study?
Does adding rosuvastatin to valsartan improve vascular dysfunction in nondiabetic patients undergoing peritoneal dialysis?
RCT (n=124)
Open-label
randomly assigned
Does adding rosuvastatin to valsartan improve vascular dysfunction in nondiabetic patients undergoing peritoneal dialysis?
Adding rosuvastatin to valsartan improves endothelial function more than valsartan alone in nondiabetic peritoneal dialysis patients, though its effect on arterial stiffness is less clear.
BACKGROUND: Statins and angiotensin receptor blockers (ARBs) are known to improve vascular dysfunction in patients with chronic kidney disease. However, these effects have been inconsistent in dialysis patients. Moreover, it is currently unknown whether adding statins to ARBs improves vascular dysfunction better than ARB monotherapy in these patients. METHODS: We conducted a prospective open randomized trial to investigate the effects of statin add-on to ARB on vascular protection in 124 nondiabetic patients undergoing peritoneal dialysis (PD). Initially, all patients received 80 mg/day of valsartan for 6 months. Excluding 10 patients who dropped out during this period, patients were randomly assigned to continue ARB treatment alone (n = 57) or to receive 10 mg/day of rosuvastatin (n = 57) added to ARB for the next 6 months. To assess vascular function, endothelium-dependent vasodilation and arterial stiffness were determined by brachial artery flow-mediated dilation (FMD) and brachial-ankle pulse wave velocity (baPWV), respectively. RESULTS: Compared to baseline values, ARB treatment for the first 6 months significantly improved FMD% (2.97 ± 2.64 to 3.57 ± 2.58 %, P < 0.001). In addition, there was a small but significant decrease in baPWV during this period (1691.5 ± 276.3 to 1635.0 ± 278.6 cm/s, P = 0.048). After randomization, add-on treatment further improved FMD% (3.57 ± 2.73 to 4.24 ± 2.77 %, P = 0.003), whereas ARB monotherapy did not (P = 0.02 for between-group difference). Further slight improvement in baPWV (1617.0 ± 280.9 to 1528.9 ± 266.8 cm/s, P = 0.021) was observed only in the combined treatment group (P = 0.28 for between-group difference). CONCLUSIONS: Adding a statin to the ARB was of some help in improving vascular dysfunction more effectively than ARB monotherapy in nondiabetic PD patients. However, whether such limited improvements can lead to better clinical outcomes requires further investigation.
No takes yet. Share an insight, caveat, or question.
Han et al. (2011) conducted an RCT in nondiabetic patients undergoing peritoneal dialysis (n=124). Rosuvastatin vs. ARB treatment alone (valsartan 80 mg/day) was evaluated on brachial artery flow-mediated dilation (FMD) (p=0.02). Adding 10 mg/day rosuvastatin to valsartan significantly improved flow-mediated dilation compared to valsartan alone in nondiabetic peritoneal dialysis patients (P=0.02 for between-group difference).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: